UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 156

Sortiert nach

The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML

Nature reviews. Cancer, 2020-03, Vol.20 (3), p.158

2020

Volltextzugriff (PDF)

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape

Leukemia, 2021-05, Vol.35 (5), p.1229-1242

2021

Volltextzugriff (PDF)

The application of BH3 mimetics in myeloid leukemias

Cell death & disease, 2021-02, Vol.12 (2), p.222-13, Article 222

2021

Volltextzugriff (PDF)

Targeting hedgehog in hematologic malignancy

Blood, 2012-03, Vol.119 (10), p.2196-2204

2012

Volltextzugriff (PDF)

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Leukemia, 2020-06, Vol.34 (6), p.1613-1625

2020

Volltextzugriff (PDF)

BRD4-mediated repression of p53 is a target for combination therapy in AML

Nature communications, 2021-01, Vol.12 (1), p.241-16, Article 241

2021

Volltextzugriff (PDF)

Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity

British journal of haematology, 2022-12, Vol.199 (5), p.665-678

Copland, Mhairi

2022

Volltextzugriff (PDF)

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Nature (London), 2016-06, Vol.534 (7607), p.341-346

2016

Volltextzugriff (PDF)

Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing

Nature communications, 2024-03, Vol.15 (1), p.1931-1931, Article 1931

2024

Volltextzugriff (PDF)

Implementing the EffTox dose-finding design in the Matchpoint trial

BMC medical research methodology, 2017-07, Vol.17 (1), p.112-15, Article 112

2017

Volltextzugriff (PDF)

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile

Blood, 2013-08, Vol.122 (7), p.1293-1304

2013

Volltextzugriff (PDF)

Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells

Nature communications, 2023-08, Vol.14 (1), p.4634-4634, Article 4634

2023

Volltextzugriff (PDF)

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Blood, 2011-06, Vol.117 (24), p.6660-6668

2011

Volltextzugriff (PDF)

Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease

Nature communications, 2024-01, Vol.15 (1), p.651-651, Article 651

2024

Volltextzugriff (PDF)

Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

Cell death discovery, 2021-06, Vol.7 (1), p.137-137, Article 137

2021

Volltextzugriff (PDF)

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

Stem cells (Dayton, Ohio), 2014-09, Vol.32 (9), p.2324-2337

2014

Volltextzugriff (PDF)

DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML

Genome biology, 2014-08, Vol.15 (8), p.406-406, Article 406

2014

Volltextzugriff (PDF)

Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche

Nature communications, 2024-02, Vol.15 (1), p.1090-1090, Article 1090

2024

Volltextzugriff (PDF)

Spred1 deficit promotes treatment resistance and transformation of chronic phase CML

Leukemia, 2022-02, Vol.36 (2), p.492-506

2022

Volltextzugriff (PDF)

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

The Lancet. Haematology, 2017-07, Vol.4 (7), p.e310-e316

2017

Volltextzugriff (PDF)

Targeting BCR-ABL1-positive leukaemias: a review article

Cambridge prisms. Precision medicine, 2023, Vol.1, p.e21-e21, Article e21

2023

Volltextzugriff (PDF)

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

Cell death discovery, 2021-07, Vol.7 (1), p.171-171, Article 171

2021

Volltextzugriff (PDF)

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

Cancer research (Chicago, Ill.), 2008-12, Vol.68 (23), p.9624-9633

2008

Volltextzugriff (PDF)

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Leukemia, 2020-07, Vol.34 (7), p.1975-1975

2020

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(151)
Mit Volltextzugriff
(145)

Publikationsform

Sprache

Englisch
(156)
Japanisch
(18)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Blood
(62)
British Journal Of Haematology
(11)
Leukemia
(5)
Nature Communications
(5)
The Lancet. Haematology
(5)
The lancet. Haematology
(5)
Blood Advances
(4)
Cancer Research
(3)
Cell Death Discovery
(3)
Current Hematologic Malignancy Reports
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape

The application of BH3 mimetics in myeloid leukemias

Targeting hedgehog in hematologic malignancy

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

BRD4-mediated repression of p53 is a target for combination therapy in AML

Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia

Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing

Implementing the EffTox dose-finding design in the Matchpoint trial

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile

Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease

Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML

Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche

Spred1 deficit promotes treatment resistance and transformation of chronic phase CML

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

Targeting BCR-ABL1-positive leukaemias: a review article

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Suchergebnisse filtern